Trade Group Calls For mRNA Vaccines As Guangzhou Starts Lock Downs
Executive Summary
Following Shanghai, China’s third-largest city Guangzhou is now on high alert as Omicron cases spread, while pharma and biotech face severe production and supply chain disruptions.
You may also be interested in...
CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.
China's mRNA Shot Shows Benefits Over Older COVID Vaccines
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.
Shanghai Reopens, Beijing Offers Policy Relief As Pharma Embraces Uncertain Future
China’s largest commercial center and pharma industry hub reopens after over two months of strict lockdown.